Novo Nordisk Faces Class Action Lawsuit Over Monopoly of Diabetes Drug Victoza
Image Source : https://tsdr.uspto.gov/#caseNumber=76123758&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
On January 23, 2026, Novo Nordisk faced a class action lawsuit in New York federal court, accused of abusing its patent rights to maintain its market monopoly over the diabetes drug Victoza.
The complaint alleges that Novo Nordisk colluded with generic drug manufacturer Teva Pharmaceutical Industries to implement a “pay-for-delay” scheme. Through a patent litigation settlement agreement, Novo Nordisk and Teva allegedly delayed the launch of Teva’s generic version—which should have entered the market in 2023—until 2024, unlawfully postponing the availability of cheaper generic drugs.
Victoza, approved by the U.S. Food and Drug Administration in 2010, was Novo's first-generation GLP-1 drug. The lawsuit said that Novo sold more than $5 billion worth of the drug in the United States in 2018.
-------
Reference Materials: